Myeloproliferative Neoplasms

Prithviraj Bose, MD, discusses treatment for patients with progressive myelofibrosis.

Ruben A. Mesa, MD, discusses new trials and agents in the pipeline in myelofibrosis.

David S. Snyder, MD, discusses the utility of transplant in myeloproliferative neoplasms.

The FDA has granted a breakthrough therapy designation to the combination of APR-246 and azacitidine for the treatment of patients with myelodysplastic syndromes with a susceptible TP53 mutation.

The combination of ruxolitinib (Jakafi) plus low-dose pegylated interferon-a2 demonstrated an improvement in peripheral blood cell counts bone marrow cellularity and fibrosis, and symptom burden with acceptable toxicity in patients with polycythemia vera or proliferative myelofibrosis.

Jacqueline S. Garcia, MD, discusses the design and findings of a phase II trial of navitoclax and details next steps for the BCL-XL/BCL-2 inhibitor.

Ruben Mesa, MD, discusses findings from a pooled analysis of fedratinib at full dose in patients with myelofibrosis who had low platelet counts.

Srikanth Nagalla, MD, discusses the management of cancer-related thrombosis in myeloproliferative neoplasms, as well as updates in immune thrombocytopenic purpura.

Marina Kremyanskaya, MD, discusses the effect of CPI-0610 in patients with myelofibrosis.

Ruben A. Mesa, MD, discusses the approval of fedratinib in myelofibrosis and other JAK inhibitors in the treatment pipeline.